Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran war drives global fertilizer prices up, raising food cost fears - 2EU foreign ministers commemorate Russian massacre in Bucha
- 3A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- 4Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- 5Are your hormones imbalanced? Doctors explain how to know if you need testing
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- Step by step instructions to Buy a Jeep Wrangler on a Senior's Spending plan
- Novartis eyes more bolt-on acquisitions, CEO says
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Toyota Reports 2.3% Sales Drop as China Weakness Deepens
- Flu cases are rising with a strain that makes older people sicker
- What to know about cheese voluntarily recalled in 20 states
